Список литературы

Основные статьи

World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach – second edition, 2016. June 2016 [internet publication].Полный текст external link opens in a new window

Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. October 2018 [internet publication].Полный текст external link opens in a new window

World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva, Switzerland: WHO Press; 2007 [internet publication].Полный текст external link opens in a new window

Статьи, указанные как источники

1. Worobey M. The origins and diversifications of HIV. In: Volberding P, Sande M, Lange J, et al., eds. Global HIV/AIDS medicine. Philadelphia, PA: Elsevier; 2008.

2. Wilson D, Naidoo S, Bekker LG, et al. Handbook of HIV medicine. South Africa: Oxford University Press; 2002.

3. Robertson DL, Anderson JP, Bradac JL, et al. HIV-1 nomenclature proposal. Science. 2000 Apr 7;288(5463):55-6.Аннотация external link opens in a new window

4. Gottlieb GS, Raugi DN, Smith RA. 90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2. Lancet HIV. 2018 Jul;5(7):e390-9.Аннотация external link opens in a new window

5. Fidler S, Fox J. Primary HIV infection: a medical and public health emergency requiring rapid specialist management. Clin Med (Lond). 2016 Apr;16(2):180-3.Полный текст external link opens in a new windowАннотация external link opens in a new window

6. World Health Organization. HIV/AIDS: fact sheet. July 2018 [internet publication].Полный текст external link opens in a new window

7. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2017 - 2016 data. November 2017 [internet publication].Полный текст external link opens in a new window

8. Public Health England. New HIV diagnoses across the UK fell by 17 per cent in 2017. 4 September 2018 [internet publicaton].Полный текст external link opens in a new window

9. Brown AE, Mohammed H, Ogaz D, et al. Fall in new HIV diagnoses among men who have sex with men (MSM) at selected London sexual health clinics since early 2015: testing or treatment or pre-exposure prophylaxis (PrEP)? Euro Surveill. 2017 Jun 22;22(25):30553.Полный текст external link opens in a new windowАннотация external link opens in a new window

10. Centers for Disease Control and Prevention. HIV surveillance report, 2016; volume 28. August 2018 [internet publication].Полный текст external link opens in a new window

11. Singh S, Song R, Johnson AS, et al. HIV incidence, HIV prevalence, and undiagnosed HIV infections in men who have sex with men, United States. Ann Intern Med. 2018 May 15;168(10):685-94.Аннотация external link opens in a new window

12. UNAIDS. Global AIDS update 2016. May 2016 [internet publication].Полный текст external link opens in a new window

13. Centers for Disease Control and Prevention. HIV in the United States: at a glance. August 2018 [internet publication].Полный текст external link opens in a new window

14. Tavoschi L, Gomes Dias J, Pharris A; EU/EEA HIV Surveillance Network. New HIV diagnoses among adults aged 50 years or older in 31 European countries, 2004-15: an analysis of surveillance data. Lancet HIV. 2017 Nov;4(11):e514-21.Аннотация external link opens in a new window

15. Pope M, Hause AT. Transmission, acute HIV-1 infection and the quest to prevent infection. Nat Med. 2003 Jul;9(7):847-52.Аннотация external link opens in a new window

16. Gupta R, Hill A, Sawyer AW, et al. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis. 2008 Sep 1;47(5):712-22.Полный текст external link opens in a new windowАннотация external link opens in a new window

17. Morris L, Cilliers T. Viral structure, replication, tropism, pathogenesis and natural history. In: Abdool Karim SS, Abdool Karim Q, eds. HIV/AIDS in South Africa. Cambridge University Press; 2005:79-89.

18. Kaplan EH, Heimer R. HIV incidence among New Haven needle exchange participants: updated estimates from syringe tracking and testing data. J Acquir Immune Def Syndr Hum Retrovirol. 1995 Oct 1;10(2):175-6.Аннотация external link opens in a new window

19. Varghese B, Maher JE, Peterman TA, et al. Reducing the risk of sexual HIV transmission: quantifying the per-act risk for HIV on the basis of choice of partner, sex act, and condom use. Sex Transm Dis. 2002 Jan;29(1):38-43.Аннотация external link opens in a new window

20. European Study Group on Heterosexual Transmission of HIV. Comparison of female to male and male to female transmission of HIV in 563 stable couples. BMJ. 1992 Mar 28;304(6830):809-13.Полный текст external link opens in a new windowАннотация external link opens in a new window

21. Bell DM. Occupational risk of human immunodeficiency virus infection in health care workers: an overview. Am J Med. 1997 May 19;102(5B):9-15.Аннотация external link opens in a new window

22. Cooper ER, Charurat M, Mofenson L, et al; Women and Infants' Transmission Study Group. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):484-94.Аннотация external link opens in a new window

23. Polis CB, Curtis KM, Hannaford PC, et al. An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women. AIDS. 2016 Nov 13;30(17):2665-83.Полный текст external link opens in a new windowАннотация external link opens in a new window

24. Tepper NK, Krashin JW, Curtis KM, et al. Update to CDC's US medical eligibility criteria for contraceptive use, 2016: revised recommendations for the use of hormonal contraception among women at high risk for HIV infection. MMWR Morb Mortal Wkly Rep. 2017 Sep 22;66(37):990-4.Полный текст external link opens in a new windowАннотация external link opens in a new window

25. World Health Organization. Hormonal contraceptive eligibility for women at high risk of HIV. 2017 [internet publication].Полный текст external link opens in a new window

26. Looker KJ, Elmes JAR, Gottlieb SL, et al. Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis. Lancet Infect Dis. 2017 Dec;17(12):1303-16.Полный текст external link opens in a new windowАннотация external link opens in a new window

27. Riddell J 4th, Amico KR, Mayer KH. HIV preexposure prophylaxis: a review. JAMA. 2018 Mar 27;319(12):1261-1268.Аннотация external link opens in a new window

28. Delaugerre C, Rodriguez C, Capitant C, et al. Drug resistance among patients who acquired HIV infection in a preexposure prophylaxis trial. AIDS. 2018;32(16):2353-61.Аннотация external link opens in a new window

29. Desai M, Field N, Grant R, et al. Recent advances in pre-exposure prophylaxis for HIV. BMJ. 2017 Dec 11;359:j5011.Полный текст external link opens in a new windowАннотация external link opens in a new window

30. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach – second edition, 2016. June 2016 [internet publication].Полный текст external link opens in a new window

31. Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States - 2017 update. March 2018 [internet publication].Полный текст external link opens in a new window

32. Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel. JAMA. 2018 Jul 24;320(4):379-96.Полный текст external link opens in a new windowАннотация external link opens in a new window

33. Grulich AE, Guy R, Amin J, et al. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study. Lancet HIV. 17 Oct 2018 [Epub ahead of print].Полный текст external link opens in a new windowАннотация external link opens in a new window

34. Holt M, Lea T, Mao L, et al. Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013-17. Lancet HIV. 2018 Aug;5(8):e448-56.Аннотация external link opens in a new window

35. Anglemyer A, Rutherford GW, Horvath T, et al. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev. 2013;(4):CD009153.Полный текст external link opens in a new windowАннотация external link opens in a new window

36. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. October 2018 [internet publication].Полный текст external link opens in a new window

37. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011 Aug 11;365(6):493-505.Полный текст external link opens in a new windowАннотация external link opens in a new window

38. Rodger AJ, Cambiano V, Bruun T, et al; PARTNER Study Group. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA. 2016 Jul 12;316(2):171-81.Полный текст external link opens in a new windowАннотация external link opens in a new window

39. Bavinton BR, Pinto AN, Phanuphak N, et al; Opposites Attract Study Group. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV. 2018 Aug;5(8):e438-47.Аннотация external link opens in a new window

40. PARTNER Study Group. HIV transmission risk through condomless sex in gay couples with suppressive ART: the PARTNER2 Study extended results in gay men. 2018 [internet publication].Полный текст external link opens in a new window

41. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007 Feb 24;369(9562):657-66.Аннотация external link opens in a new window

42. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007 Feb 24;369(9562):643-56.Аннотация external link opens in a new window

43. Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005 Nov;2(11):e298.Полный текст external link opens in a new windowАннотация external link opens in a new window

44. Weiss HA, Quigley MA, Hayes RJ. Male circumcision and risk of HIV infection in sub-Saharan Africa: a systemic review and meta-analysis. AIDS. 2000 Oct 20;14(15):2361-70.Аннотация external link opens in a new window

45. Tobian AA, Serwadda D, Quinn TC, et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med. 2009 Mar 26;360(13):1298-309.Полный текст external link opens in a new windowАннотация external link opens in a new window

46. Mills E, Cooper C, Anema A, et al. Male circumcision for the prevention of heterosexually acquired HIV infection: a meta-analysis of randomized trials involving 11,050 men. HIV Med. 2008 Jul;9(6):332-5.Аннотация external link opens in a new window

47. Delany-Moretlwe S, Gray G, Kagee A, et al. AIDS prevention in South Africa. South Afr J HIV Med. 2006;23:13-7.

48. Rubens M, Ramamoorthy V, Saxena A, et al. HIV vaccine: recent advances, current roadblocks, and future directions. J Immunol Res. 2015;2015:560347.Полный текст external link opens in a new windowАннотация external link opens in a new window

49. Leal L, Lucero C, Gatell JM, et al. New challenges in therapeutic vaccines against HIV infection. Expert Rev Vaccines. 2017 Jun;16(6):587-600.Аннотация external link opens in a new window

50. Marshall BDL, Goedel WC, King MRF, et al. Potential effectiveness of long-acting injectable pre-exposure prophylaxis for HIV prevention in men who have sex with men: a modelling study. Lancet HIV. 2018 Jun 13 [Epub ahead of print].Аннотация external link opens in a new window

51. Centers for Disease Control and Prevention. Laboratory testing for the diagnosis of HIV infection: updated recommendations. June 2014 [internet publication].Полный текст external link opens in a new window

52. Centers for Disease Control and Prevention. Revised surveillance case definition for HIV infection: United States, 2014. MMWR Recomm Rep. 2014;63(RR-03):1-10.Полный текст external link opens in a new windowАннотация external link opens in a new window

53. World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva, Switzerland: WHO Press; 2007 [internet publication].Полный текст external link opens in a new window

54. UNAIDS, World Health Organization. UNAIDS/WHO policy statement on HIV testing. June 2004 [internet publication].Полный текст external link opens in a new window

55. World Health Organization. HIV drug resistance report 2017. July 2017 [internet publication].Полный текст external link opens in a new window

56. Shepher J, Quinn T. Laboratory testing for HIV infection. In: Volberding P, Sande M, Lange J, et al., eds. Global HIV/AIDS medicine. Philadelphia, PA: Elsevier; 2008:101-7.

57. Deeks SG, Gange SJ, Kitahata MM, et al. Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis. 2009 Nov 15;49(10):1582-90.Полный текст external link opens in a new windowАннотация external link opens in a new window

58. Aves T, Tambe J, Siemieniuk RA, et al. Antiretroviral resistance testing in HIV-positive people. Cochrane Database Syst Rev. 2018 Nov 9;11:CD006495. doi: 10.1002/14651858.CD006495.pub5. [Epub ahead of print]Полный текст external link opens in a new windowАннотация external link opens in a new window

59. Centers for Disease Control and Prevention. 2015 sexually transmitted diseases treatment guidelines: sexual assault and abuse and STDs. June 2015 [internet publication].Полный текст external link opens in a new window

60. World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. July 2017 [internet publication].Полный текст external link opens in a new window

61. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006 Sep 22;55(RR-14):1-17;quiz CE1-4.Полный текст external link opens in a new windowАннотация external link opens in a new window

62. DiNenno EA, Prejean J, Irwin K, et al. Recommendations for HIV screening of gay, bisexual, and other men who have sex with men - United States, 2017. MMWR Morb Mortal Wkly Rep. 2017 Aug 11;66(31):830-2.Полный текст external link opens in a new windowАннотация external link opens in a new window

63. Pitasi MA, Oraka E, Clark H, et al. HIV testing among transgender women and men - 27 states and Guam, 2014-2015. MMWR Morb Mortal Wkly Rep. 2017 Aug 25;66(33):883-7.Полный текст external link opens in a new windowАннотация external link opens in a new window

64. Pitasi MA, Delaney KP, Oraka E, et al. Interval since last HIV test for men and women with recent risk for HIV infection - United States, 2006-2016. MMWR Morb Mortal Wkly Rep. 2018 Jun 22;67(24):677-81.Полный текст external link opens in a new windowАннотация external link opens in a new window

65. The Voluntary HIV Counseling and Testing Efficacy Study Group. Efficacy of voluntary HIV-1 counselling and testing in individuals and couples in Kenya, Tanzania and Trinidad: a randomised trial. Lancet. 2000 Jul 8;356(9224):103-12.Аннотация external link opens in a new window

66. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. May 2018 [internet publication].Полный текст external link opens in a new window

67. Grobler L, Siegfried N, Visser ME, et al. Nutritional interventions for reducing morbidity and mortality in people with HIV. Cochrane Database Syst Rev. 2013 Feb 28;(2):CD004536.Полный текст external link opens in a new windowАннотация external link opens in a new window

68. Olsen MF, Abdissa A, Kaestel P, et al. Effects of nutritional supplementation for HIV patients starting antiretroviral treatment: randomised controlled trial in Ethiopia. BMJ. 2014 May 15;348:g3187.Полный текст external link opens in a new windowАннотация external link opens in a new window

69. Visser ME, Durao S, Sinclair D, et al. Micronutrient supplementation in adults with HIV infection. Cochrane Database Syst Rev. 2017 May 18;(5):CD003650.Полный текст external link opens in a new windowАннотация external link opens in a new window

70. US Department of Health and Human Services. HIV and immunizations. 6 February 2018 [internet publication].Полный текст external link opens in a new window

71. Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015 Aug 27;373(9):795-807.Полный текст external link opens in a new windowАннотация external link opens in a new window

72. Thumath M, Sandstra I, Forrest J, et al. Implementation of a rapid referral pathway to HIV treatment for gay men and MSM diagnosed with acute HIV-infection in sexual health clinics in British Columbia. Abstract TUPED782. In: Program and abstracts of the 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-22 July 2015. Vancouver, Canada.

73. Cahn P, Madero JS, Arribas J, et al. Non-inferior efficacy of dolutegravir (DTG) plus lamivudine (3TC) versus DTG plus tenofovir/emtricitabine (TDF/FTC) fixed-dose combination in antiretroviral treatment-naive adults with HIV-1 infection - 48-week results from the GEMINI studies. Paper presented at: 22nd International AIDS Conference (AIDS 2018). 2018. Amsterdam, Netherlands.Полный текст external link opens in a new windowАннотация external link opens in a new window

74. Wang H, Lu X, Yang X, et al. The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: meta-analysis. Medicine (Baltimore). 2016 Oct;95(41):e5146.Полный текст external link opens in a new windowАннотация external link opens in a new window

75. Food and Drug Administration. FDA drug safety communication: FDA to evaluate potential risk of neural tube birth defects with HIV medicine dolutegravir (Juluca, Tivicay, Triumeq). May 2018 [internet publication].Полный текст external link opens in a new window

76. European Medicines Agency. New study suggests risk of birth defects in babies born to women on HIV medicine dolutegravir. May 2018 [internet publication].Полный текст external link opens in a new window

77. World Health Organization. Guidelines on the public health response to pretreatment HIV drug resistance: supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: second edition June 2016. July 2017 [internet publication].Полный текст external link opens in a new window

78. Lennox JL, Landovitz RJ, Ribaudo HJ, et al; ACTG A5257 Team. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014 Oct 7;161(7):461-71.Полный текст external link opens in a new windowАннотация external link opens in a new window

79. Lederman MM, Calabrese L, Funderburg NT, et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis. 2011 Oct 15;204(8):1217-26.Полный текст external link opens in a new windowАннотация external link opens in a new window

80. Lindegren ML, Kennedy CE, Bain-Brickley D, et al. Integration of HIV/AIDS services with maternal, neonatal and child health, nutrition, and family planning services. Cochrane Database Syst Rev. 2012 Sep 12;(9):CD010119.Полный текст external link opens in a new windowАннотация external link opens in a new window

81. Islam FM, Wu J, Jansson J, et al. Relative risk of cardiovascular disease among people living with HIV: A systematic review and meta-analysis. HIV Med. 2012 Sep;13(8):453-68.Аннотация external link opens in a new window

82. Segarra-Newnham M. Osteoporosis and vitamin D deficiency in HIV-positive patients. J Pharm Technol. 2011;27:251-7.

83. Emu B, Fessel J, Schrader S, et al. Phase 3 study of ibalizumab for multidrug-resistant HIV-1. N Engl J Med. 2018 Aug 16;379(7):645-54.Аннотация external link opens in a new window

84. Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017 Sep 23;390(10101):1499-510.Аннотация external link opens in a new window

85. Li L, Tian JH, Yang K, et al. Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection. Cochrane Database Syst Rev. 2014 Jul 26;(7):CD008439.Полный текст external link opens in a new windowАннотация external link opens in a new window

86. Lalezari JP, Latiff GH, Brinson C, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial. Lancet HIV. 2015 Oct;2(10):e427-37.Аннотация external link opens in a new window

87. Murgatroyd C, Pirrie L, Tran F, et al. Structure-activity relationships of the human immunodeficiency virus type 1 maturation inhibitor PF-46396. J Virol. 2016 Aug 26;90(18):8181-97.Полный текст external link opens in a new windowАннотация external link opens in a new window

88. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003 May 12;163(9):1009-21.Полный текст external link opens in a new windowАннотация external link opens in a new window

89. O'Connor J, Smith C, Lampe FC, et al. Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study. Lancet HIV. 2017 Jul;4(7):e295-302.Полный текст external link opens in a new windowАннотация external link opens in a new window

90. Nance RM, Delaney JAC, Simoni JM, et al. HIV viral suppression trends over time among HIV-infected patients receiving care in the United States, 1997 to 2015: a cohort study. Ann Intern Med. 2018;169(6):376-84.Полный текст external link opens in a new windowАннотация external link opens in a new window

91. Teeraananchai S, Kerr SJ, Amin J, et al. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis. HIV Med. 2017 Apr;18(4):256-66.Аннотация external link opens in a new window

92. Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017 Aug;4(8):e349-56.Полный текст external link opens in a new windowАннотация external link opens in a new window

93. Engels EA, Yanik EL, Wheeler W, et al. Cancer-attributable mortality among people with treated human immunodeficiency virus infection in North America. Clin Infect Dis. 2017 Aug 15;65(4):636-43.Полный текст external link opens in a new window

94. Mandalia S, Westrop SJ, Beck EJ, et al. Are long-term non-progressors very slow progressors? Insights from the Chelsea and Westminster HIV Cohort, 1988-2010. PLoS One. 2012;7(2):e29844.Полный текст external link opens in a new windowАннотация external link opens in a new window

95. Lawn SD, Wilkinson RJ, Lipman MC, et al. Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy. Am J Resp Crit Care Med. 2008 Apr 1;177(7):680-5.Аннотация external link opens in a new window

96. Shah ASV, Stelzle D, Lee KK, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV. Circulation. 2018;138(11):1100-12.Полный текст external link opens in a new windowАннотация external link opens in a new window

97. Losina E, Hyle EP, Borre ED, et al. Projecting 10-yr, 20-yr and lifetime risks of cardiovascular disease in persons living with HIV in the US. Clin Infect Dis. 2017 Oct 15;65(8):1266-71.Аннотация external link opens in a new window

98. Beckman JA, Duncan MS, Alcorn CW, et al. Association of human immunodeficiency virus infection and risk of peripheral artery disease. Circulation. 2018 Jul 17;138(3):255-65.Полный текст external link opens in a new windowАннотация external link opens in a new window

99. Ryom L, Lundgren JD, El-Sadr W, et al. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. Lancet HIV. 2018 Jun;5(6):e291-300.Аннотация external link opens in a new window

100. Osibogun O, Ogunmoroti O, Michos ED, et al. HIV/HCV coinfection and the risk of cardiovascular disease: a meta-analysis. J Viral Hepat. 2017 Nov;24(11):998-1004.Аннотация external link opens in a new window

101. Abraham AG, Althoff KN, Jing Y, et al. End-stage renal disease among HIV-infected adults in North America. Clin Infect Dis. 2015 Mar 15;60(6):941-9.Полный текст external link opens in a new windowАннотация external link opens in a new window

102. Hileman CO, Eckard AR, McComsey GA. Bone loss in HIV: a contemporary review. Curr Opin Endocrinol Diabetes Obes. 2015 Dec;22(6):446-51.Аннотация external link opens in a new window

103. Crum-Cianflone N, Hullsiek KH, Marconi V, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS. 2009 Jan 2;23(1):41-50.Полный текст external link opens in a new windowАннотация external link opens in a new window

104. Yanik EL, Napravnik S, Cole SR, et al. Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. Clin Infect Dis. 2013 Sep;57(5):756-64.Полный текст external link opens in a new windowАннотация external link opens in a new window

105. Silverberg MJ, Chao C, Leyden WA, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2551-9.Полный текст external link opens in a new windowАннотация external link opens in a new window

106. Silverberg MJ, Lau B, Achenbach CJ, et al. Cumulative incidence of cancer among persons with HIV in North America: a cohort study. Ann Intern Med. 2015 Oct 6;163(7):507-18.Полный текст external link opens in a new windowАннотация external link opens in a new window

107. Morlat P, Roussillon C, Henard S, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS. 2014 May 15;28(8):1181-91.Аннотация external link opens in a new window

108. Hessol NA, Whittemore H, Vittinghoff E, et al. Incidence of first and second primary cancers diagnosed among people with HIV, 1985-2013: a population-based, registry linkage study. Lancet HIV. 20 September 2018 [Epub before print].Полный текст external link opens in a new windowАннотация external link opens in a new window

109. Park LS, Tate JP, Sigel K, et al. Association of viral suppression with lower AIDS-defining and non-AIDS-defining cancer incidence in HIV-infected veterans: a prospective cohort study. Ann Intern Med. 2018 Jul 17;169(2):87-96.Аннотация external link opens in a new window

110. Klein MB, Althoff KN, Jing Y, et al. Risk of end-stage liver disease in HIV-viral hepatitis coinfected persons in North America from the early to modern antiretroviral therapy eras. Clin Infect Dis. 2016;63:1160-7.Полный текст external link opens in a new windowАннотация external link opens in a new window

111. Chan P, Brew BJ. HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment. Curr HIV/AIDS Rep. 2014 Sep;11(3):317-24.Аннотация external link opens in a new window

112. Eshun-Wilson I, Siegfried N, Akena DH, et al. Antidepressants for depression in adults with HIV infection. Cochrane Database Syst Rev. 2018;(1):CD008525.Полный текст external link opens in a new windowАннотация external link opens in a new window

113. Monroe AK, Glesby MJ, Brown TT, et al. Diagnosing and managing diabetes in HIV-infected patients: current concepts. Clin Infect Dis. 2015 Feb 1;60(3):453-62.Полный текст external link opens in a new windowАннотация external link opens in a new window

114. Nduka CU, Stranges S, Kimani PK, et al. Is there sufficient evidence for a causal association between antiretroviral therapy and diabetes in HIV-infected patients? A meta-analysis. Diabetes Metab Res Rev. 2017 Sep;33(6).Аннотация external link opens in a new window

115. Bhatia R, Murphy AB, Raper JL, et al. Testosterone replacement therapy among HIV-infected men in the CFAR Network of Integrated Clinical Systems. AIDS. 2015 Jan 2;29(1):77-81.Полный текст external link opens in a new windowАннотация external link opens in a new window

116. Crothers K, Morris A. HIV infection and lung function decline: challenges, clinical implications, and new questions. AIDS. 2013 May 15;27(8):1345-7.Аннотация external link opens in a new window

117. Ensink RJH, Kuper H. Is hearing impairment associated with HIV? A systematic review of data from low- and middle-income countries. Trop Med Int Health. 2017 Dec;22(12):1493-504.Аннотация external link opens in a new window

118. Kuhar DT, Henderson DK, Struble KA, et al; US Public Health Service Working Group. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol. 2013 Sep;34(9):875-92.Полный текст external link opens in a new windowАннотация external link opens in a new window

119. Centers for Disease Control and Prevention, US Department of Health and Human Services. Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV - United States, 2016. April 2018 [internet publication].Полный текст external link opens in a new window

120. Brooks JT, Kawwass JF, Smith DK, et al. Effects of antiretroviral therapy to prevent HIV transmission to women in couples attempting conception when the man has HIV infection - United States, 2017. MMWR Morb Mortal Wkly Rep. 2017 Aug 18;66(32):859-60.Полный текст external link opens in a new windowАннотация external link opens in a new window

121. Kawwass JF, Smith DK, Kissin DM, et al. Strategies for preventing HIV infection among HIV-uninfected women attempting conception with HIV-infected men - United States. MMWR Morb Mortal Wkly Rep. 2017 Jun 2;66(21):554-7.Полный текст external link opens in a new windowАннотация external link opens in a new window

122. National Institute for Health and Care Excellence. HIV testing: increasing uptake among people who may have undiagnosed HIV. December 2016 [internet publication].Полный текст external link opens in a new window

123. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010 Sep 3;329(5996):1168-74.Полный текст external link opens in a new windowАннотация external link opens in a new window

124. Fowler MG, Newell ML. Breast-feeding and HIV-1 transmission in resource-limited settings. J Acquir Immune Defic Syndr. 2002 Jun 1;30(2):230-9.Аннотация external link opens in a new window

Использование этого контента попадает под действие нашего заявления об отказе от ответственности